Get the Stockscreener App
18.03
4.34%
0.75
Ceribell Inc stock is traded at $18.03, with a volume of 708.89K.
It is up +4.34% in the last 24 hours and up +8.75% over the past month.
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
See More
Previous Close:
$17.28
Open:
$17.63
24h Volume:
708.89K
Relative Volume:
2.39
Market Cap:
$684.11M
Revenue:
$95.07M
Net Income/Loss:
$-60.37M
P/E Ratio:
-11.07
EPS:
-1.6291
Net Cash Flow:
$-50.92M
1W Performance:
-0.66%
1M Performance:
+8.75%
6M Performance:
-15.55%
1Y Performance:
+1.29%
1-Day Range:
$17.45
$18.08
1-Week Range:
$17.07
$18.80
52-Week Range:
$10.85
$24.33
Ceribell Inc Stock (CBLL) Company Profile
Name
Ceribell Inc
Sector
Industry
Phone
(800) 436-0826
Address
360 N. PASTORIA AVENUE, SUNNYVALE
Compare CBLL vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
18.03 | 684.11M | 95.07M | -60.37M | -50.92M | -1.6291 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Raymond James | Strong Buy |
| Jun-24-25 | Initiated | BTIG Research | Buy |
| Apr-04-25 | Initiated | Ladenburg Thalmann | Buy |
| Nov-05-24 | Initiated | BofA Securities | Buy |
| Nov-05-24 | Initiated | Canaccord Genuity | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
View All
Ceribell Inc Stock (CBLL) Latest News
CeriBell Inc (CBLL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CeriBell Inc (CBLL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CeriBell Inc (CBLL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ceribell, Inc. identifies hidden seizure in child using rapid EEG in emergency room - Traders Union
CeriBell Inc (CBLL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Insider Sell Alert: Joseph Taylor Sells 5,500 Shares of CeriBell Inc (CBLL) - GuruFocus
High-Profile Insider Move Shakes Up Investor Buzz at Ceribell, Inc. - TipRanks
Ceribell director Joseph Taylor sells $101,255 in common stock By Investing.com - Investing.com South Africa
Ceribell director Joseph Taylor sells $101,255 in common stock - Investing.com
CeriBell Inc. (CBLL) Q1 2026 Earnings: EPS Miss of 30.7% Highlights Rising Costs, No Revenue ReportedForward Guidance Trends - newsline.com
Ceribell, Inc. launches FDA-cleared device for bedside diagnosis and delirium monitoring - Traders Union
CBLL Q1 2026 Earnings: EPS Misses Estimates, Stock Shows ResilienceEarnings Outlook Update - newsline.com
Ceribell Insider Sold Shares Worth $714,870, According to a Recent SEC Filing - Moomoo
CBLL Q1 2026 Earnings: EPS Misses Estimates as Losses Widen, Shares DeclinePre-Earnings Drift - newsline.com
Ceribell CEO Chao sells $714,870 in common stock By Investing.com - Investing.com Nigeria
Ceribell CEO Chao sells $714,870 in common stock - Investing.com
CeriBell Inc. (CBLL) Shows Strength with 4% Gain: Technical Levels and Market ContextIsland Reversal - newsline.com
FDA-approved ceribell EEG shortens seizure diagnosis by monitoring brain activity - CBS News
Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes - The Manila Times
Ceribell Announces New Critical Care Medicine Publication - GlobeNewswire
CBLL Q1 2026 Earnings: Wider-than-Expected Loss Disappoints InvestorsSlow Growth Warning - newsline.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
William Blair Maintains Ceribell(CBLL.US) With Buy Rating - Moomoo
Ceribell Announces Director Elections at 2026 Annual Meeting - The Globe and Mail
CBLL Technical Analysis | Trend, Signals & Chart Patterns | CERIBELL INC (NASDAQ:CBLL) - ChartMill
InvestingPro’s Fair Value warned of CeriBell crash 17 months ago By Investing.com - Investing.com
CeriBell Inc. (CBLL) Q1 2026 Earnings: Wider-than-Expected Loss Weighs on SharesRevenue Per Share - newsline.com
Ceribell Leadership Unloads Shares in a Wave of Insider Stock Moves - TipRanks
CeriBell (CBLL) Holds Near Support Amid Modest GainsFibonacci Fan - newsline.com
EEG adoption accelerates in urgent seizure detection, Ceribell, Inc. pushes - Traders Union
CeriBell Inc. (CBLL) Q1 2026 Earnings: EPS Misses Estimates by 30.7%, Stock Edges HigherFull Year Guidance - newsline.com
Ceribell CEO to present at William Blair Growth Stock Conference on June 3, 2026 - Pluang
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference - Moomoo
Earnings call transcript: Ceribell Inc. Q1 2026 misses EPS, revenue up - Investing.com Nigeria
Bank of America Securities Remains a Buy on Ceribell, Inc. (CBLL) - The Globe and Mail
Canaccord Genuity maintains Ceribell (CBLL) buy recommendation - MSN
Ceribell anticipates $112M-$116M 2026 revenue while targeting delirium NTAP of up to $2,171 per patient - MSN
CeriBell Sees ‘Early Innings’ Growth as Hospital Accounts and Usage Hit Records - Yahoo Finance
Ladenburg Thalmann Maintains Ceribell(CBLL.US) With Buy Rating, Maintains Target Price $32 - Moomoo
Middle East Tensions Threaten Ceribell’s Supply Chain, Shipping Routes, and Margins - TipRanks
Ceribell’s Earnings Call Signals Growth Over Profits - The Globe and Mail
TD Cowen Maintains Ceribell(CBLL.US) With Buy Rating, Maintains Target Price $29 - Moomoo
A Quick Look at Today's Ratings for Ceribell(CBLL.US), With a Forecast Between $25 to $29 - Moomoo
Canaccord lowers Ceribell stock price target on valuation compression By Investing.com - Investing.com Australia
Canaccord lowers Ceribell stock price target on valuation compression - Investing.com
Ceribell: Buy Rating Reiterated on Strong Q1 Momentum and Expanded TAM, $28 Price Target Maintained - TipRanks
Ceribell, Inc. (CBLL) reports Q1 loss, beats revenue estimates - MSN
Ceribell Inc Stock (CBLL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):